Literature DB >> 21639404

Special considerations with insulin therapy in older adults with diabetes mellitus.

Arshag D Mooradian1.   

Abstract

Aging is associated with alterations in insulin secretion and action. However, aging per se does not alter the pharmacokinetics of commercially available insulin and its analogues. Insulin therapy in older adults is complicated by psychosocial and physiological changes of aging. Several new insulin and insulin analogue preparations are now available for clinical use. Used as prandial (e.g. insulin lispro, insulin aspart or insulin glulisine) and basal insulin (e.g. insulin glargine, insulin detemir), these analogues simulate physiological insulin profiles more closely than the older conventional insulins. The availability of multiple insulin products provides new opportunities to achieve control of diabetes mellitus. The choice of initial insulin therapy can be made based on blood glucose profiles. Overall, these profiles can be divided into three general patterns that include: (i) round-the-clock hyperglycaemia; (ii) fasting hyperglycaemia with daytime euglycaemia; and (iii) daytime hyperglycaemia with normal fasting blood glucose levels. The prescription of insulin is a dynamic process, and the insulin regimen should be adjusted based on individual response. The goal of diabetes care in older adults is to enhance quality of life without subjecting individuals to complicated treatment regimens that may interfere with their independence in carrying out daily activities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21639404     DOI: 10.2165/11590570-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  58 in total

1.  Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes.

Authors:  B Rami; E Schober
Journal:  Eur J Pediatr       Date:  1997-11       Impact factor: 3.183

Review 2.  Review of clinical trials: update on oral insulin spray formulation.

Authors:  Paolo Pozzilli; Philip Raskin; Christopher G Parkin
Journal:  Diabetes Obes Metab       Date:  2009-11-02       Impact factor: 6.577

3.  Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

Authors:  James K Malone; Lisa F Kerr; Barbara N Campaigne; Richard A Sachson; John H Holcombe
Journal:  Clin Ther       Date:  2004-12       Impact factor: 3.393

4.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

Review 5.  Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States.

Authors:  Jerome E Thurman
Journal:  Endocr Pract       Date:  2007-10       Impact factor: 3.443

6.  Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Authors:  Edoardo Mannucci; Matteo Monami; Daniela Balzi; Barbara Cresci; Laura Pala; Cecilia Melani; Caterina Lamanna; Ilaria Bracali; Michela Bigiarini; Alessandro Barchielli; Niccolo Marchionni; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

Review 7.  Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.

Authors:  Smiljana Ristic; Peter C Bates
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

8.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

9.  Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.

Authors:  K Rave; E Potocka; L Heinemann; T Heise; A H Boss; M Marino; D Costello; R Chen
Journal:  Diabetes Obes Metab       Date:  2009-05-19       Impact factor: 6.577

Review 10.  Insulin glulisine. Aventis Pharma.

Authors:  Daniela Barlocco
Journal:  Curr Opin Investig Drugs       Date:  2003-10
View more
  5 in total

Review 1.  Diabetes and altered glucose metabolism with aging.

Authors:  Rita Rastogi Kalyani; Josephine M Egan
Journal:  Endocrinol Metab Clin North Am       Date:  2013-03-22       Impact factor: 4.741

Review 2.  Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis.

Authors:  Kirsten Nørgaard; Nithya Sukumar; Snorri B Rafnsson; Ponnusamy Saravanan
Journal:  Diabetes Ther       Date:  2018-04-05       Impact factor: 2.945

3.  Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Authors:  Eddy Karnieli; Florian M M Baeres; Grzegorz Dzida; Qiuhe Ji; Robert Ligthelm; Stuart Ross; Anne Louise Svendsen; Jean-François Yale
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

4.  Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study.

Authors:  Robyn K Pollom; Timothy Costigan; Lyndon B Lacaya; Liza L Ilag; Priscilla A Hollander
Journal:  Diabetes Ther       Date:  2018-03-14       Impact factor: 2.945

5.  Effectiveness of a Community Health Worker-Led Diabetes Intervention among Older and Younger Latino Participants: Results from a Randomized Controlled Trial.

Authors:  Barbara Mendez Campos; Edith C Kieffer; Brandy Sinco; Gloria Palmisano; Michael S Spencer; Gretchen A Piatt
Journal:  Geriatrics (Basel)       Date:  2018-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.